Home » Sensipar Generics Granted Approval by FDA
Sensipar Generics Granted Approval by FDA
Drugs Submissions and Approvals
The FDA granted approval for the first generic versions of Amgen’s Sensipar (cinacalcet hydrochloride), a calcium reducer, to treat a thyroid issue for certain patients on dialysis.
In February, a U.S. District Judge shot down Amgen’s attempt to obtain six more months of market exclusivity from the FDA, a decision which the drug manufacturer stated it would appeal.
Sensipar earned Amgen $1.72 billion in 2017, accounting for 9% of the company’s revenue.